CASE REPORT article
Front. Nutr.
Sec. Nutrition and Microbes
Volume 12 - 2025 | doi: 10.3389/fnut.2025.1594022
This article is part of the Research TopicDietary Modulation of Gut Microbiota-X axisView all 11 articles
Therapeutic Efficacy of Fecal Microbiota Transplantation in Severe Food Intolerance: A Case Report
Provisionally accepted
Yanhui Huang1
Jiayuan Huang2Tianyu Xu2Guoqiao Quan2Yuange Li2Peihao Xu2Xiaoya Yang3*
Zhou Liu4*
Wenrui Xie2*- 1First Clinical Medical College, Guangdong Medical University, Zhanjiang, Guangdong Province, China
- 2The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China
- 3Guangzhou Health Science College, Guangzhou, China
- 4Department of Neurology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This report presents the first documented application of fecal microbiota transplantation (FMT) for the management of extensive multi-food intolerance involving 52 specific foods in a pediatric patient with autism spectrum disorder (ASD). A 7-year-old autistic child was diagnosed with food intolerance to 52 items, presenting with generalized rashes, diarrhea, and malnutrition (BMI of 12.9) upon exposure or ingestion of the implicated foods. The child received oral fecal microbiota capsule treatment, with a daily dose of 9 capsules (a total of 120 capsules per course) for two consecutive treatment courses. The rashes resolved, the child regained tolerance to previously intolerable foods, nutritional status improved, and stool consistency normalized. This case suggests that FMT may hold therapeutic potential for managing food intolerance in autistic patients.
Keywords: food intolerance, fecal microbiota transplantation, Gut Microbiota, Autism Spectrum Disorder, Gastrointestinal symptoms
Received: 17 Mar 2025; Accepted: 18 Apr 2025.
Copyright: © 2025 Huang, Huang, Xu, Quan, Li, Xu, Yang, Liu and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiaoya Yang, Guangzhou Health Science College, Guangzhou, China
Zhou Liu, Department of Neurology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
Wenrui Xie, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.